The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
Dr. Tony Wood, chief scientific officer of GSK, said in a statement that Blujepa’s approval is “a crucial milestone.” “We are ...
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
1d
Verywell Health on MSNA New FDA-Approved Antibiotic May Help Women With Recurring UTIsIf you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...
The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections (uUTIs) in adult females ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results